MARKETWISE, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MARKETWISE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $512.40M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $549.18M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $364.18M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $272.22M | Mar 10, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $328.12M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $408.70M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $448.18M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $512.40M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $549.18M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $360.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $265.40M | Mar 10, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.62M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $7.06M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.78M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $17.99M | Mar 6, 2025 |
| FY2022 | Dec 31, 2021 | $18.25M | Mar 31, 2023 |
| FY2022 | Jul 21, 2021 | ($1.03B) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($29.63M) | May 10, 2021 |
| FY2021 | Dec 31, 2019 | $27.96M | Mar 10, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.60M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $88.99M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $51.81M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $87.28M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | ($967.59M) | Mar 7, 2024 |
| FY2020 | Dec 31, 2020 | ($349.9K) | May 10, 2021 |
| FY2021 | Dec 31, 2019 | $25.57M | Mar 10, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.81M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $9.91M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $8.83M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $8.82M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $7.49M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $4.77M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $3.67M | Mar 10, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.96M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($22.15M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $62.43M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $48.37M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $63.63M | Mar 7, 2024 |
| FY2020 | Dec 31, 2020 | ($592.4K) | May 10, 2021 |
| FY2021 | Dec 31, 2019 | $54.20M | Mar 10, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $391.0K | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $133.0K | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $65.0K | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $35.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $157.0K | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $290.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $177.0K | Mar 10, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $218.38M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $259.52M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $396.56M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $442.51M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $421.55M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $284.81M | Mar 10, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $432.00M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $477.44M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $685.50M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $740.89M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $826.82M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.21B | Mar 10, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.68M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($12.54M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($11.08M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($21.20M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($48.55M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | $5.00M | May 10, 2021 |
| FY2020 | Feb 10, 2020 | $0 | May 10, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.04M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $30.04M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $31.04M | Mar 6, 2026 |
| FY2025 | Dec 31, 2022 | $31.31M | Mar 6, 2026 |
| FY2024 | Dec 31, 2021 | $23.29M | Mar 6, 2025 |
| FY2023 | Dec 31, 2020 | $18.10M | Mar 7, 2024 |
| FY2021 | Dec 31, 2019 | $18.10M | Mar 10, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($113.66M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($119.28M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($126.34M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($128.13M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($146.12M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($29.63M) | May 10, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.14M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $97.88M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $155.17M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $158.58M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $139.08M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $114.42M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $170.52M | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 7, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 7, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jul 23, 2020 | 10.35M | May 10, 2021 |